|
 |
|||||||||||||||||||
|
|||||||||||||||||||
|
|||||||||||||||||||
 |
 |
|
|
a Research Unit in Systemic Autoimmune Diseases, Vall d'Hebron Research Institute, Hospital Vall d'Hebron, Barcelona, Spain
Key Words: systemic lupus erythematosus • T cells • DNA methylation
Address for correspondence: Dr. Eva Balada, Research Unit in Systemic Autoimmune Diseases, Vall d'Hebron Research Institute, Hospital Vall d'Hebron, Passeig Vall d'Hebron 119-129-08035 Barcelona, Spain. Voice: 34-93-489-40-47; fax: 34-93-489-40-45. ebalada{at}ir.vhebron.net
Several studies have indicated the importance of DNA hypomethylation in the etiology of systemic lupus erythematosus (SLE). Different enzymes linked to the DNA methylation process have been described. The identification of all these enzymes means that cells have the capacity to modify their methylation patterns. Therefore, to obtain a deeper understanding of the role this epigenetic mechanism may have on SLE, the enzymes involved in the DNA methylation mechanism must be thoughtfully analyzed. In fact, studies of enzymes (other than DNMT1) in this autoimmune disease are still lacking. We have recently investigated the simultaneous gene expression of DNMT1, DNMT3A, DNMT3B, MBD2, and MBD4 in SLE patients. Here we review some of the studies that focus on the relationship between DNA methylation and SLE as well as we report our recent findings in this field. We suggest some alternative hypothesis that could help to understand the causes of the global DNA hypomethylation observed in the CD4+ T cells of these patients.
|
 |
 |
